Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 42 | 2024 | 2029 | 8.920 |
Why?
|
| Isoniazid | 11 | 2023 | 288 | 2.320 |
Why?
|
| Mycobacterium tuberculosis | 9 | 2024 | 1930 | 2.220 |
Why?
|
| Peru | 17 | 2024 | 890 | 2.120 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 10 | 2021 | 944 | 1.950 |
Why?
|
| Antitubercular Agents | 15 | 2023 | 1397 | 1.590 |
Why?
|
| Tuberculosis, Pulmonary | 4 | 2021 | 843 | 1.550 |
Why?
|
| Tuberculin Test | 4 | 2020 | 205 | 1.420 |
Why?
|
| Contact Tracing | 6 | 2020 | 275 | 1.080 |
Why?
|
| Health Facilities | 4 | 2022 | 578 | 0.920 |
Why?
|
| Latent Tuberculosis | 3 | 2022 | 224 | 0.920 |
Why?
|
| Private Sector | 2 | 2024 | 396 | 0.880 |
Why?
|
| Delayed Diagnosis | 2 | 2024 | 467 | 0.850 |
Why?
|
| Mass Screening | 9 | 2023 | 5458 | 0.850 |
Why?
|
| Health Services Accessibility | 6 | 2024 | 5520 | 0.750 |
Why?
|
| Kenya | 10 | 2023 | 757 | 0.750 |
Why?
|
| HIV Infections | 16 | 2023 | 17569 | 0.660 |
Why?
|
| Family Characteristics | 6 | 2020 | 1003 | 0.650 |
Why?
|
| Genome, Bacterial | 1 | 2024 | 796 | 0.630 |
Why?
|
| National Health Programs | 3 | 2021 | 442 | 0.610 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 857 | 0.540 |
Why?
|
| Comprehensive Health Care | 1 | 2017 | 123 | 0.520 |
Why?
|
| Mycobacterium | 1 | 2015 | 252 | 0.460 |
Why?
|
| Sputum | 4 | 2023 | 517 | 0.450 |
Why?
|
| Mycobacterium bovis | 1 | 2013 | 148 | 0.430 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1088 | 0.420 |
Why?
|
| Health Literacy | 1 | 2018 | 466 | 0.400 |
Why?
|
| Adolescent | 27 | 2022 | 89169 | 0.390 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2021 | 1967 | 0.370 |
Why?
|
| Young Adult | 18 | 2024 | 60066 | 0.360 |
Why?
|
| Child | 24 | 2023 | 80917 | 0.340 |
Why?
|
| Anti-Retroviral Agents | 2 | 2018 | 1789 | 0.330 |
Why?
|
| Humans | 60 | 2025 | 768166 | 0.320 |
Why?
|
| Public Health | 1 | 2022 | 2679 | 0.310 |
Why?
|
| Infant | 16 | 2022 | 36535 | 0.300 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 7852 | 0.290 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 2337 | 0.290 |
Why?
|
| Child, Preschool | 16 | 2021 | 42669 | 0.290 |
Why?
|
| Lesotho | 2 | 2025 | 76 | 0.270 |
Why?
|
| Drug Therapy, Combination | 4 | 2022 | 6316 | 0.270 |
Why?
|
| Communicable Diseases | 1 | 2015 | 874 | 0.260 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 3415 | 0.260 |
Why?
|
| Phylogeny | 1 | 2013 | 2843 | 0.260 |
Why?
|
| Comorbidity | 2 | 2019 | 10590 | 0.260 |
Why?
|
| Prevalence | 8 | 2019 | 15869 | 0.250 |
Why?
|
| Adult | 22 | 2024 | 223646 | 0.240 |
Why?
|
| Fluoroquinolones | 2 | 2020 | 309 | 0.240 |
Why?
|
| Health Policy | 1 | 2017 | 2698 | 0.240 |
Why?
|
| Infant, Newborn | 11 | 2021 | 26422 | 0.230 |
Why?
|
| Bacterial Typing Techniques | 2 | 2016 | 263 | 0.230 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 5367 | 0.220 |
Why?
|
| Clinical Protocols | 2 | 2021 | 1443 | 0.200 |
Why?
|
| Public Sector | 1 | 2024 | 266 | 0.200 |
Why?
|
| Middle Aged | 17 | 2024 | 223492 | 0.200 |
Why?
|
| Pakistan | 2 | 2022 | 299 | 0.200 |
Why?
|
| Models, Theoretical | 4 | 2021 | 3573 | 0.190 |
Why?
|
| Transportation | 1 | 2022 | 217 | 0.180 |
Why?
|
| X-Rays | 1 | 2021 | 311 | 0.170 |
Why?
|
| Prisons | 1 | 2022 | 178 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 3231 | 0.170 |
Why?
|
| Prisoners | 1 | 2023 | 316 | 0.170 |
Why?
|
| Male | 21 | 2025 | 364719 | 0.170 |
Why?
|
| Incidence | 7 | 2021 | 21538 | 0.170 |
Why?
|
| Rifampin | 1 | 2021 | 352 | 0.160 |
Why?
|
| Patient-Centered Care | 2 | 2021 | 1444 | 0.160 |
Why?
|
| Female | 22 | 2025 | 397192 | 0.160 |
Why?
|
| Health Personnel | 2 | 2024 | 3385 | 0.160 |
Why?
|
| Mobile Health Units | 1 | 2019 | 93 | 0.160 |
Why?
|
| Focus Groups | 1 | 2023 | 1460 | 0.140 |
Why?
|
| Cleft Lip | 1 | 2021 | 512 | 0.130 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 752 | 0.130 |
Why?
|
| Cleft Palate | 1 | 2021 | 596 | 0.130 |
Why?
|
| Health Care Reform | 1 | 2025 | 1256 | 0.120 |
Why?
|
| Child Mortality | 1 | 2017 | 204 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2023 | 54926 | 0.120 |
Why?
|
| Community Health Services | 1 | 2019 | 659 | 0.110 |
Why?
|
| Rifamycins | 1 | 2013 | 27 | 0.110 |
Why?
|
| Russia | 1 | 2015 | 386 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2025 | 3140 | 0.110 |
Why?
|
| Emigration and Immigration | 1 | 2016 | 406 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2019 | 6340 | 0.100 |
Why?
|
| Optometry | 1 | 2012 | 29 | 0.100 |
Why?
|
| Indians, North American | 1 | 2016 | 354 | 0.100 |
Why?
|
| World Health Organization | 1 | 2018 | 1329 | 0.100 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 807 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2022 | 2118 | 0.100 |
Why?
|
| BCG Vaccine | 1 | 2015 | 381 | 0.100 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 718 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2022 | 81762 | 0.100 |
Why?
|
| Family | 1 | 2022 | 3209 | 0.090 |
Why?
|
| Epidemics | 1 | 2017 | 517 | 0.090 |
Why?
|
| Sex Factors | 3 | 2019 | 10632 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2015 | 1194 | 0.090 |
Why?
|
| Survivors | 1 | 2021 | 2381 | 0.090 |
Why?
|
| Anti-HIV Agents | 2 | 2017 | 4573 | 0.090 |
Why?
|
| Aged | 8 | 2021 | 171504 | 0.080 |
Why?
|
| Mortality | 1 | 2021 | 2911 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 14729 | 0.080 |
Why?
|
| Risk Factors | 6 | 2021 | 74944 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2015 | 1474 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 5536 | 0.080 |
Why?
|
| Health Promotion | 1 | 2020 | 2210 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2017 | 1951 | 0.070 |
Why?
|
| Logistic Models | 1 | 2022 | 13290 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2019 | 9669 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2022 | 8080 | 0.070 |
Why?
|
| Cross Infection | 1 | 2015 | 1426 | 0.070 |
Why?
|
| Intraocular Pressure | 1 | 2012 | 1304 | 0.070 |
Why?
|
| Ophthalmology | 1 | 2012 | 560 | 0.060 |
Why?
|
| Internet | 1 | 2018 | 3110 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 1063 | 0.060 |
Why?
|
| Mental Health | 1 | 2020 | 3275 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2022 | 22291 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 26379 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2014 | 2596 | 0.050 |
Why?
|
| Glaucoma | 1 | 2012 | 1194 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 8748 | 0.050 |
Why?
|
| Vaccination | 1 | 2015 | 3437 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2014 | 1885 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2012 | 2235 | 0.050 |
Why?
|
| Genotype | 1 | 2016 | 13045 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2012 | 2523 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12543 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 24315 | 0.040 |
Why?
|
| Nepal | 1 | 2021 | 301 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12077 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2023 | 340 | 0.040 |
Why?
|
| Indonesia | 1 | 2020 | 131 | 0.040 |
Why?
|
| Lebanon | 1 | 2020 | 245 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 629 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 5889 | 0.040 |
Why?
|
| United States | 3 | 2016 | 73039 | 0.040 |
Why?
|
| Autopsy | 1 | 2022 | 1011 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2025 | 2741 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2017 | 6874 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2018 | 204 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2018 | 41754 | 0.030 |
Why?
|
| Primary Health Care | 2 | 2025 | 4746 | 0.030 |
Why?
|
| Age Distribution | 1 | 2021 | 2873 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 7454 | 0.030 |
Why?
|
| Gonioscopy | 1 | 2012 | 157 | 0.020 |
Why?
|
| Tonometry, Ocular | 1 | 2012 | 238 | 0.020 |
Why?
|
| Hospitals, District | 1 | 2012 | 114 | 0.020 |
Why?
|
| Schools | 1 | 2020 | 1498 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2020 | 2507 | 0.020 |
Why?
|
| Cause of Death | 1 | 2022 | 3721 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 59629 | 0.020 |
Why?
|
| Visual Field Tests | 1 | 2012 | 415 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5315 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 2748 | 0.020 |
Why?
|
| Self Report | 1 | 2020 | 3773 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 1157 | 0.020 |
Why?
|
| Visual Fields | 1 | 2012 | 1065 | 0.020 |
Why?
|
| Algorithms | 1 | 2023 | 14164 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18412 | 0.010 |
Why?
|
Concepts
(155)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(24)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_